Annovis Bio, Inc. (ANVS)
- Reuters
UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study
Annovis Bio's on Monday reported data that showed its Alzheimer's disease drug failed to show statistical significance in meeting the goals of a mid-stage trial sending its shares tumbling as much as 60%. The trial tested the drug buntanetap in patients with mild-to-moderate Alzheimer's disease (AD) along two scales assessing cognition and cognitive dysfunction. In a press release, the company said a "post-hoc" analysis of the trial data had shown statistically significant results in improving cognition function scores along an Alzheimer's disease scale in a subgroup of patients who had mild disease and who tested positive for certain disease biomarkers.
- GlobeNewswire
Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild ADImprovement in cognition measured by ADAS-Cog 11 at three months is 3.3 points as compared to 0.3 for placebo, consistent with our previous Phase II AD/PD and Discover studies Plasma Tau protein levels are reduced, consistent with our previous Phase II biomarker dataBased on the findings of this symptomatic study, Annovis plans to conduct a pivotal disease-modifying
- Zacks
Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 198% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
